Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simonetta Viviani

Showing results (41-50 of 111) with videos related to

Pageof 12
Sort By:
Human Vaccines & Immunotherapeutics|October 1, 2016
Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adultsChukiat Sirivichayakul, Pornthep Chanthavanich, Kriengsak Limkittikul, et al.
Pathogens (Basel, Switzerland)|August 6, 2021
West Nile Virus Seroprevalence in the Italian Tuscany Region from 2016 to 2019Serena Marchi, Emanuele Montomoli, Simonetta Viviani, et al.
Journal of Preventive Medicine and Hygiene|January 6, 2025
Improving the ONE HEALTH approach: a lesson from SARS-CoV-2 pandemicSerena Marchi, Giovanni Guarducci, Maria Giovanna Marotta, et al.
Viruses|July 27, 2022
SARS-CoV-2 Circulation during the First Year of the Pandemic: A Seroprevalence Study from January to December 2020 in Tuscany, ItalySerena Marchi, Gianvito Lanave, Michele Camero, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 5, 2015
Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patientsPier Luigi Zinzani, Umberto Vitolo, Simonetta Viviani, et al.
Leukemia & Lymphoma|June 10, 2010
Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experienceSimonetta Viviani, Massimo Di Nicola, Valeria Bonfante, et al.
Human Vaccines & Immunotherapeutics|March 15, 2022
A serological investigation in Southern Italy: was SARS-CoV-2 circulating in late 2019?Claudia Maria Trombetta, Serena Marchi, Simonetta Viviani, et al.
Acta Tropica|November 14, 2022
Neutralizing activity of African lineage Zika virus immune sera towards Asian lineageSerena Marchi, Filippo Dragoni, Adele Boccuto, et al.
The Journal of Infectious Diseases|October 15, 2021
Phase 1 Randomized, Placebo-Controlled, Dose-Escalating Study to Evaluate OVX836, a Nucleoprotein-Based Influenza Vaccine: Intramuscular ResultsKanchanamala Withanage, Ilse De Coster, Nathalie Cools, et al.
The Oncologist|February 12, 2015
Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centersCarmelo Carlo-Stella, Francesca Ricci, Serena Dalto, et al.
Pageof 12

Showing results (41-50 of 111) with videos related to

Sort By:
Pageof 12
Human Vaccines & Immunotherapeutics|October 1, 2016
Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adultsChukiat Sirivichayakul, Pornthep Chanthavanich, Kriengsak Limkittikul, et al.
Pathogens (Basel, Switzerland)|August 6, 2021
West Nile Virus Seroprevalence in the Italian Tuscany Region from 2016 to 2019Serena Marchi, Emanuele Montomoli, Simonetta Viviani, et al.
Journal of Preventive Medicine and Hygiene|January 6, 2025
Improving the ONE HEALTH approach: a lesson from SARS-CoV-2 pandemicSerena Marchi, Giovanni Guarducci, Maria Giovanna Marotta, et al.
Viruses|July 27, 2022
SARS-CoV-2 Circulation during the First Year of the Pandemic: A Seroprevalence Study from January to December 2020 in Tuscany, ItalySerena Marchi, Gianvito Lanave, Michele Camero, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 5, 2015
Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patientsPier Luigi Zinzani, Umberto Vitolo, Simonetta Viviani, et al.
Leukemia & Lymphoma|June 10, 2010
Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experienceSimonetta Viviani, Massimo Di Nicola, Valeria Bonfante, et al.
Human Vaccines & Immunotherapeutics|March 15, 2022
A serological investigation in Southern Italy: was SARS-CoV-2 circulating in late 2019?Claudia Maria Trombetta, Serena Marchi, Simonetta Viviani, et al.
Acta Tropica|November 14, 2022
Neutralizing activity of African lineage Zika virus immune sera towards Asian lineageSerena Marchi, Filippo Dragoni, Adele Boccuto, et al.
The Journal of Infectious Diseases|October 15, 2021
Phase 1 Randomized, Placebo-Controlled, Dose-Escalating Study to Evaluate OVX836, a Nucleoprotein-Based Influenza Vaccine: Intramuscular ResultsKanchanamala Withanage, Ilse De Coster, Nathalie Cools, et al.
The Oncologist|February 12, 2015
Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centersCarmelo Carlo-Stella, Francesca Ricci, Serena Dalto, et al.
Pageof 12